Comparing Baudax Bio (NASDAQ:BXRX) & Curative Biotechnology (OTCMKTS:CUBT)
Comparing Baudax Bio (NASDAQ:BXRX) & Curative Biotechnology (OTCMKTS:CUBT)
Curative Biotechnology (OTCMKTS:CUBT – Get Rating) and Baudax Bio (NASDAQ:BXRX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
醫治生物科技(場外交易代碼：CUBT-GET評級)和博達克斯生物(納斯達克：BXRX-GET評級)都是小盤醫療公司，但哪種投資更好？我們將根據風險的強弱、分析師的建議、盈利能力、股息、機構所有權、收益和估值對這兩家公司進行比較。
Institutional and Insider Ownership
機構和內部人持股
21.1% of Baudax Bio shares are held by institutional investors. 0.5% of Baudax Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Baudax Bio 21.1%的股份由機構投資者持有。Baudax Bio 0.5%的股份由內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一隻股票有望實現長期增長。
Earnings & Valuation
收益與估值
This table compares Curative Biotechnology and Baudax Bio's revenue, earnings per share and valuation.
該表格比較了Treatate Biotech和Baudax Bio的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curative Biotechnology | N/A | N/A | N/A | N/A | N/A |
| Baudax Bio | $1.08 million | 1.45 | -$19.77 million | ($1.17) | -0.16 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 治療性生物技術 | 不適用 | 不適用 | 不適用 | 不適用 | 不適用 |
| Baudax Bio | 108萬美元 | 1.45 | -1977萬美元 | ($1.17) | -0.16 |
Analyst Ratings
分析師評級
This is a summary of recent recommendations and price targets for Curative Biotechnology and Baudax Bio, as provided by MarketBeat.
這是由MarketBeat提供的針對治癒生物技術和Baudax Bio的最近建議和目標價的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curative Biotechnology | 0 | 0 | 0 | 0 | N/A |
| Baudax Bio | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 治療性生物技術 | 0 | 0 | 0 | 0 | 不適用 |
| Baudax Bio | 0 | 0 | 1 | 0 | 3.00 |
Baudax Bio has a consensus price target of $1.00, indicating a potential upside of 421.10%. Given Baudax Bio's higher possible upside, analysts clearly believe Baudax Bio is more favorable than Curative Biotechnology.
博達克斯生物公司的一致目標價為1.00美元，這表明潛在的上漲幅度為421.10。考慮到Baudax Bio更有可能的上行空間，分析師們顯然認為Baudax Bio比治癒生物技術公司更有利。
Profitability
盈利能力
This table compares Curative Biotechnology and Baudax Bio's net margins, return on equity and return on assets.
此表比較了治癒生物技術公司和Baudax Bio公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Curative Biotechnology | N/A | N/A | N/A |
| Baudax Bio | -561.08% | -486.60% | -15.40% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 治療性生物技術 | 不適用 | 不適用 | 不適用 |
| Baudax Bio | -561.08% | -486.60% | -15.40% |
Volatility & Risk
波動性與風險
Curative Biotechnology has a beta of -19.29, indicating that its stock price is 2,029% less volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.
根治生物科技的貝塔係數為-19.29，表明其股價的波動性比標準普爾500指數低2029%。相比之下，Baudax Bio的貝塔係數為1.64，這表明其股價的波動性比標準普爾500指數高64%。
Summary
摘要
Baudax Bio beats Curative Biotechnology on 6 of the 9 factors compared between the two stocks.
Baudax Bio在兩隻股票比較的9個因素中有6個擊敗了治癒生物科技。
About Curative Biotechnology
關於治療性生物技術
(Get Rating)
(獲取評級)
Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.
醫療生物技術公司是一家處於發展階段的生物醫學公司，專注於罕見疾病的新療法。該公司專注於因疾病、治療本身的性質或臨牀開發階段而可能加速開發路徑的治療方法。它正在開發的候選藥物包括CURB906，一種針對CD56陽性腦瘤的抗體-藥物結合物；以及IMT504，一種治療狂犬病的新型免疫療法。該公司已與中大西洋生物治療公司達成協議，開發新冠肺炎疫苗。醫治生物技術公司成立於1995年，總部設在佛羅裏達州博卡拉頓。
About Baudax Bio
關於Baudax Bio
(Get Rating)
(獲取評級)
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Baudax Bio，Inc.是一家制藥公司，開發和銷售用於醫院和其他急性護理環境的產品。該公司提供ANJESO(美洛昔康)注射，單獨或與非NSAID止痛藥聯合使用，用於治療中到重度疼痛。該公司正在開發的產品包括處於第二階段臨牀試驗的中效神經肌肉阻滯劑(NMB)BX1000、處於第一階段臨牀試驗的超短效NMBA藥物BX2000、NMBA逆轉劑BX3000以及右美託咪定的鼻腔專利製劑Dex-IN。該公司成立於2019年，總部設在賓夕法尼亞州馬爾文。
Receive News & Ratings for Curative Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curative Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《治療性生物技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對治癒生物技術和相關公司的評級的每日摘要。
譯文內容由第三人軟體翻譯。